Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CYTK's Cash to Debt is ranked higher than
96% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. CYTK: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CYTK' s Cash to Debt Range Over the Past 10 Years
Min: 2.9  Med: 53.80 Max: No Debt
Current: No Debt
Equity to Asset 0.66
CYTK's Equity to Asset is ranked lower than
52% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYTK: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
CYTK' s Equity to Asset Range Over the Past 10 Years
Min: -1.73  Med: 0.82 Max: 0.96
Current: 0.66
-1.73
0.96
Interest Coverage No Debt
CYTK's Interest Coverage is ranked higher than
94% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTK: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYTK' s Interest Coverage Range Over the Past 10 Years
Min: 63.8  Med: 10000.00 Max: 9999.99
Current: No Debt
63.8
9999.99
F-Score: 3
Z-Score: -1.47
M-Score: -5.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -49.10
CYTK's Operating margin (%) is ranked higher than
54% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. CYTK: -49.10 )
Ranked among companies with meaningful Operating margin (%) only.
CYTK' s Operating margin (%) Range Over the Past 10 Years
Min: -1961.56  Med: -488.25 Max: 32
Current: -49.1
-1961.56
32
Net-margin (%) -48.77
CYTK's Net-margin (%) is ranked higher than
55% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. CYTK: -48.77 )
Ranked among companies with meaningful Net-margin (%) only.
CYTK' s Net-margin (%) Range Over the Past 10 Years
Min: -1912.57  Med: -464.00 Max: 30.1
Current: -48.77
-1912.57
30.1
ROE (%) -25.29
CYTK's ROE (%) is ranked higher than
54% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. CYTK: -25.29 )
Ranked among companies with meaningful ROE (%) only.
CYTK' s ROE (%) Range Over the Past 10 Years
Min: -85.46  Med: -55.74 Max: 32.47
Current: -25.29
-85.46
32.47
ROA (%) -17.79
CYTK's ROA (%) is ranked higher than
59% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CYTK: -17.79 )
Ranked among companies with meaningful ROA (%) only.
CYTK' s ROA (%) Range Over the Past 10 Years
Min: -73.2  Med: -42.86 Max: 23.37
Current: -17.79
-73.2
23.37
ROC (Joel Greenblatt) (%) -314.12
CYTK's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. CYTK: -314.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYTK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3507.33  Med: -766.35 Max: 570.52
Current: -314.12
-3507.33
570.52
Revenue Growth (3Y)(%) 56.80
CYTK's Revenue Growth (3Y)(%) is ranked higher than
93% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. CYTK: 56.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYTK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -43.65 Max: 154.8
Current: 56.8
0
154.8
EBITDA Growth (3Y)(%) -53.30
CYTK's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. CYTK: -53.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYTK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.3  Med: -25.05 Max: 2.5
Current: -53.3
-53.3
2.5
EPS Growth (3Y)(%) -54.30
CYTK's EPS Growth (3Y)(%) is ranked lower than
94% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CYTK: -54.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYTK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55  Med: -26.90 Max: 8.1
Current: -54.3
-55
8.1
» CYTK's 10-Y Financials

Financials (Next Earnings Date: 2016-02-16)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

CYTK Guru Trades in Q4 2014

Jim Simons Sold Out
Paul Tudor Jones 12,878 sh (-9.49%)
» More
Q1 2015

CYTK Guru Trades in Q1 2015

Jim Simons 69,467 sh (New)
Charles Brandes 18,300 sh (New)
Paul Tudor Jones 24,493 sh (+90.19%)
» More
Q2 2015

CYTK Guru Trades in Q2 2015

Jim Simons 72,400 sh (+4.22%)
Charles Brandes 18,300 sh (unchged)
Paul Tudor Jones 17,091 sh (-30.22%)
» More
Q3 2015

CYTK Guru Trades in Q3 2015

Jim Simons 219,700 sh (+203.45%)
Paul Tudor Jones 19,592 sh (+14.63%)
Charles Brandes 18,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CYTK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.94
CYTK's P/B is ranked lower than
72% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. CYTK: 3.94 )
Ranked among companies with meaningful P/B only.
CYTK' s P/B Range Over the Past 10 Years
Min: 0.89  Med: 2.26 Max: 6.94
Current: 3.94
0.89
6.94
P/S 6.50
CYTK's P/S is ranked higher than
62% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. CYTK: 6.50 )
Ranked among companies with meaningful P/S only.
CYTK' s P/S Range Over the Past 10 Years
Min: 1.84  Med: 16.37 Max: 97.81
Current: 6.5
1.84
97.81
PFCF 46.05
CYTK's PFCF is ranked lower than
68% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.21 vs. CYTK: 46.05 )
Ranked among companies with meaningful PFCF only.
CYTK' s PFCF Range Over the Past 10 Years
Min: 16.24  Med: 43.11 Max: 80.13
Current: 46.05
16.24
80.13
POCF 43.23
CYTK's POCF is ranked lower than
70% of the 383 Companies
in the Global Biotechnology industry.

( Industry Median: 28.02 vs. CYTK: 43.23 )
Ranked among companies with meaningful POCF only.
CYTK' s POCF Range Over the Past 10 Years
Min: 15.48  Med: 39.57 Max: 75.13
Current: 43.23
15.48
75.13
Current Ratio 3.33
CYTK's Current Ratio is ranked lower than
59% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. CYTK: 3.33 )
Ranked among companies with meaningful Current Ratio only.
CYTK' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 6.38 Max: 23.3
Current: 3.33
1.85
23.3
Quick Ratio 3.33
CYTK's Quick Ratio is ranked lower than
56% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. CYTK: 3.33 )
Ranked among companies with meaningful Quick Ratio only.
CYTK' s Quick Ratio Range Over the Past 10 Years
Min: 1.85  Med: 6.38 Max: 23.3
Current: 3.33
1.85
23.3
Days Sales Outstanding 0.42
CYTK's Days Sales Outstanding is ranked higher than
99% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. CYTK: 0.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.06  Med: 4.41 Max: 4910.75
Current: 0.42
0.06
4910.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.24
CYTK's Price/Net Cash is ranked higher than
61% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CYTK: 4.24 )
Ranked among companies with meaningful Price/Net Cash only.
CYTK' s Price/Net Cash Range Over the Past 10 Years
Min: 0.99  Med: 3.04 Max: 9.18
Current: 4.24
0.99
9.18
Price/Net Current Asset Value 4.09
CYTK's Price/Net Current Asset Value is ranked higher than
59% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. CYTK: 4.09 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYTK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.96  Med: 2.95 Max: 7.79
Current: 4.09
0.96
7.79
Price/Tangible Book 3.97
CYTK's Price/Tangible Book is ranked higher than
56% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CYTK: 3.97 )
Ranked among companies with meaningful Price/Tangible Book only.
CYTK' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.95  Med: 2.43 Max: 5.81
Current: 3.97
0.95
5.81
Price/Median PS Value 0.39
CYTK's Price/Median PS Value is ranked higher than
84% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYTK: 0.39 )
Ranked among companies with meaningful Price/Median PS Value only.
CYTK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 1.00 Max: 5.16
Current: 0.39
0.12
5.16
Earnings Yield (Greenblatt) (%) -11.67
CYTK's Earnings Yield (Greenblatt) (%) is ranked lower than
58% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CYTK: -11.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYTK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -11.67  Med: 34.25 Max: 238.3
Current: -11.67
-11.67
238.3

More Statistics

Revenue(Mil) $41
EPS $ -0.50
Beta1.04
Short Percentage of Float13.06%
52-Week Range $5.50 - 13.18
Shares Outstanding(Mil)38.85

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 33 34
EPS($) -1.02 -1.17
EPS without NRI($) -1.02 -1.17

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:KK3A.Germany,
Cytokinetics Inc was incorporated under the laws of the state of Delaware on August 5, 1997. The Company is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its research and development activities relating to the biology of muscle function have evolved from its knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Its advanced research and development programs relates to the biology of muscle function and are directed to small molecule modulators of the contractility of skeletal or cardiac muscle. It also conducts earlier-stage research directed to other compounds with the potential to modulate muscle contractility and other muscle functions, such as growth, energetics and metabolism. Its drug candidate from its skeletal muscle contractility program, tirasemtiv, formerly known as CK-2017357, is a fast skeletal muscle troponin activator. The Company's cardiac muscle contractility program is focused on the cardiac sarcomere, the basic unit of muscle contraction in the heart. Its drug candidate from this program, omecamtiv mecarbil, formerly known as CK-1827452, is a novel cardiac muscle myosin activator that is being developed under a strategic alliance with Amgen. It is conducting joint research with Amgen directed to next-generation compounds in its cardiac muscle contractility program. The Company is currently conducting a Phase II clinical trials program for tirasemtiv, including an ongoing Phase IIb clinical trial in patients with ALS, known as BENEFIT-ALS, Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS. It is also developing CK-2127107, a structurally distinct, fast skeletal muscle troponin activator, under a strategic alliance with Astellas. The Company competes with Mitsubishi Tanabe Pharma Corporation, Eisai Inc., Trophos SA, Neuraltus Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., GlaxoSmithKline plc., BrainStorm Cell Therapeutics and Neuralstem. The Company's research, testing, manufacturing, selling and marketing of drugs are subject to extensive regulation by the FDA and other regulatory authorities in the United States.
» More Articles for CYTK

Headlines

Articles On GuruFocus.com
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Aug 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares Jun 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares May 20 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares May 14 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) May 07 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 28 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 01 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 05 2009 
Cytokinetics Inc. (CYTK) President & CEO Robert I Blum sells 1,000 Shares Aug 06 2009 

More From Other Websites
Cytokinetics to Participate in Upcoming Investor Conferences Feb 03 2016
Cytokinetics to Announce Fourth Quarter Results on February 16, 2016 Feb 02 2016
Is Alexion (ALXN) Likely to Disappoint this Earnings Season? Feb 01 2016
GW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings? Feb 01 2016
What's in Store for Nivalis (NVLS) this Earnings Season? Jan 29 2016
Can Gilead (GILD) Keep the Earnings Streak Alive in Q4? Jan 29 2016
ImmunoGen (IMGN) Q2 Earnings Preview: What to Expect? Jan 27 2016
Celgene (CELG) to Report Q4 Earnings: What to Expect? Jan 26 2016
Will Bristol-Myers (BMY) Beat Q4 Earnings Expectations? Jan 25 2016
The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Cytokinetics and Bristol-Myers Squibb Jan 18 2016
4 Biotech Stocks Looking Good this Earnings Season Jan 15 2016
Cytokinetics Outlines Vision 2020 Strategic Initiative to Advance Portfolio of Muscle Biology Drug... Jan 11 2016
CYTOKINETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 11 2016
Cytokinetics Outlines Vision 2020 Strategic Initiative to Advance Portfolio of Muscle Biology Drug... Jan 11 2016
Cytokinetics Presents Analyses Demonstrating Predictive Value of Slow Vital Capacity for Clinical... Jan 10 2016
Cytokinetics Presents Analyses Demonstrating Predictive Value of Slow Vital Capacity for Clinical... Jan 10 2016
Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis Jan 06 2016
Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal... Jan 04 2016
CYTOKINETICS INC Files SEC form 8-K, Other Events Jan 04 2016
Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal... Jan 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK